Steve Usdin

Steve Usdin, the Washington editor, dives into the rare IPO filing by LB Pharma on NASDAQ, amidst a quiet biotech market. He discusses the surge of interest in Hong Kong's biotech scene, contrasting it with challenges faced in the U.S. The podcast explores the FDA's surprising reversal on Stealth BioTherapeutics' Barth syndrome treatment, emphasizing the need for innovation. Usdin also highlights the growing threats to U.S. biopharma innovation posed by potential clashes over intellectual property and regulatory practices.